News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Invitation To Participate In A Conference Call: Procyon BioPharma Inc. (PBP.TO) To Report The Receptor And Mode-Of-Action For PCK3145, Its Lead Drug Candidate For Advanced Metastatic Prostate Cancer



10/19/2005 5:13:04 PM

MONTREAL, April 18 /CNW Telbec/ - Procyon Biopharma Inc. (TSX: PBP) invites media representatives as well as members of the financial and scientific communities to participate in a conference call. During the conference call, Mr. Hans Mader, President and Chief Executive Officer of Procyon Biopharma and Dr. Richard BĂ©liveau from the University of Quebec in Montreal, will present the latest findings elucidating the mode-of-action and the relevant cell surface receptor of PCK3145, Procyon's therapeutic peptide for the treatment of advanced metastatic prostate cancer. The conference call will be held on Tuesday, April 19, 2005 at 9:00 am (ET). A news release will be issued on Canada Newswire (www.newswire.ca) and PR Newswire (www.prnewswire.com) prior to the event.

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES